Table 1

Summary of results from the European Randomized Study of Screening for Prostate Cancer (ERSPC) after 9–16 years of follow-up

Median follow-up (years)9111316
Positive predictive value of biopsy (%)
PCa diagnosed in screening group (No)5990696374088444
PCa diagnosed in control group (No)4307539661077732
Excess PCa incidence per 1000 men34353530
Relative PCa mortality reduction (%)20212120
Absolute PCa mortality reduction per 1000 men0.711.071.281.76
Reference number2223246
  • PCa, prostate cancer.